



XVII corso di Aggiornamento AIRTUM per Operatori dei Registri Tumori

Reggio Emilia, 27-29 settembre 2017

GIOVANNI FERRARI
UROLOGO ANDROLOGO



**SERVIZIO SANITARIO REGIONALE
EMILIA-ROMAGNA**
Azienda Unità Sanitaria Locale di Reggio Emilia
IRCCS Istituto in tecnologie avanzate e modelli assistenziali in oncologia




ANAMNESI FONDAMENTALE !!!

1. EMATURIA

- Pseudoematuria
- Ematuria medica
- Ematuria urologica




2. DOLORE




3. LUTS pollachiuria, urgenza, disuria, tenesmo, bruciori





CISTOSCOPIA

AMBULATORIALE
LUBRIFICANTE ANESTETICO
RIGIDO
FLESSIBILE









PDD del CIS

“CIS”





Luce bianca
mucosa di apparenza normale




PDD
fluorescenza del carcinoma in situ


BIOPSIA VESCICALE



CITOLOGIE URINARIE



Normal urothelial cells: Normal urothelial cells have a uniform appearance with abundant cytoplasm and small nuclei.




High grade bladder cancer: Bladder cancer cells are enlarged with large and dark nuclei.






CITOLOGIA URINARIA

- SE POSSIBILE NON DEL MATTINO (CITOLISI)
- MOLTO SENSIBILE PER IL G3
- MOLTO SENSIBILE PER IL CIS (28-100%)
- SE NEGATIVE NON ESCLUDONO
- OPERATORE DIPENDENTE ANCHE 90% DI SPECIFICITA'
- RIPETIBILE IN CASI DUBBI




ECOGRAFIA VESCICALE SOVRAPUBICA



TAC

- STADIAZIONE
- VISUALIZZAZIONE VIE ESCRETRICI SUPERIORI
- 1,8% ma 7,5% se la neoplasia vescicale interessa il trigono
- Per il CIS non serve



TEST MOLECOLARI

Table 5.1: Summary of main urinary markers

Markers (or test specifications)	Overall sensitivity (%)	Overall specificity (%)	Sensitivity for high-grade tumours (%)	Point-of-care test	LE
UroVysion (FISH)	30-86	63-95	66-70	No	2b
Microsatellite analysis	58-92	73-100	90-92	No	1b
Immunocyt/uCyt +	52-100	63-79	62-92	No	2a
Nuclear matrix Protein 22	47-100	55-98	75-92	Yes	2a
BTA stat	29-83	56-86	62-91	Yes	3
BTA TRAK	53-91	28-83	74-77	No	3
Cytokeratins	12-88	73-95	33-100	No	3

BTA = bladder tumour antigen; LE = level of evidence.

LINEE GUIDA

5.9 Guidelines for the primary assessment of NMIBC

	GR
Patient history should be taken.	A
Renal and bladder US may be used during the initial work-up in patients with haematuria.	C
At the time of the initial diagnosis of NMIBC, CT urography (or IVU) should be performed only in selected cases (e.g., tumours located in the trigone, multiple- or high-risk tumours).	B
Cystoscopy is recommended in all patients with symptoms suggestive of BC. It cannot be replaced by cytology or by any other non-invasive test.	A
Cystoscopy should describe all macroscopic features of the tumour (site, size, number and appearance) and mucosal abnormalities. A bladder diagram is recommended (Figure 5.1).	C
Voided urine cytology is advocated to predict high-grade tumour before TURB.	C
Cytology should be performed on fresh urine with adequate fixation. Morning urine is not suitable because of the frequent presence of cytolysis.	C

BC = bladder cancer; CT = computed tomography; GR = grade of recommendation; IVU = intravenous urography; US = ultrasound; NMIBC = non-muscle invasive bladder cancer; TURB = transurethral resection of the bladder.

FOLLOW UP

**NESSUN TEST PUO' SOPPIANTERE IL VALORE PREDITTIVO
DELLA CISTOSCOPIA E DELLE CITOLOGIE**

SCREENING DELLA POPOLZIONE

**LO SCREENING CON NMP22 O UROVYSION NON E' RACCOMANDATO
PER I COSTI E LA BASSA SENSIBILITA'**

E' AUSPICABILE UN TEST PREDITTIVO






GRAZIE



Figure 5.1: Bladder diagram



- | | |
|----------------------------|------------------------|
| 1 = Trigone | 6 = Anterior wall |
| 2 = Right ureteral orifice | 7 = Posterior wall |
| 3 = Left ureteral orifice | 8 = Dome |
| 4 = Right wall | 9 = Neck |
| 5 = Left wall | 10 = Posterior urethra |

